In:
Thrombosis and Haemostasis, Georg Thieme Verlag KG, Vol. 73, No. 02 ( 1995), p. 215-218
Kurzfassung:
The incidence of factor VIII inhibitor was studied in a cohort of 56 previously untreated patients with severe hemophilia A (factor VIII below 1 U/dl). They received only one brand of highly purified factor VIII concentrate (HPSD-VIII) prepared by conventional chromatography with a solvent-detergent step for viral inactivation. Followup since the first infusion of HPSD-VIII was from 1 to 76 months (mean = 29) and cumulative exposure days (CED) from 1 to over 100 (median = 26). Five patients (9%) developed an inhibitor after 6 to 19 CED, only one being a high responder (2%), showing a low incidence of inhibitor compared with previous studies using high purity plasma- derived or recombinant products.
Materialart:
Online-Ressource
ISSN:
0340-6245
,
2567-689X
DOI:
10.1055/s-0038-1653753
Sprache:
Englisch
Verlag:
Georg Thieme Verlag KG
Publikationsdatum:
1995
